Spravato Operations Series
Starting a Spravato Program: The Operational Launch Checklist
REMS certification, payer contracting lead time, the drug acquisition decision, staffing, scheduling templates, and the financial model — in the order that actually prevents launch mistakes.
The Clinical Decision Is the Easy Part
Deciding to offer Spravato (esketamine) takes a meeting. Building a program that can deliver it — certified, contracted, staffed, scheduled, and solvent — takes a project plan with real lead times, and several of the longest items cannot be compressed. The programs that launch smoothly sequence the slow things first: payer enrollment and REMS certification start months before the first patient sits in a chair. The programs that struggle announce a start date first and discover the lead times afterward.
Here is the launch sequence we use, drawn from supporting a roughly 70-patient interventional psychiatry program in Oregon that runs 12–15 sessions a day.
1. REMS Certification and Enrollment Infrastructure
The healthcare setting must be certified in the SPRAVATO REMS before it can receive or administer drug — this is a facility-level enrollment, separate from anything the prescriber holds individually. Complete the outpatient healthcare setting enrollment, designate an authorized representative, train the staff who will administer and monitor, and stock the required monitoring equipment (blood pressure monitoring and, per current requirements, a pulse oximeter). Build patient REMS enrollment into your intake packet from day one so it never becomes a day-of-treatment scramble. Requirements are updated periodically — verify the current state at spravatorems.com, and read our REMS compliance workflow for how the requirements translate into daily operations.
2. Payer Contracting and Credentialing — Start This First, It Is the Longest Pole
Spravato revenue rides on payer participation: prescriber credentialing, facility enrollment where applicable, and confirmation that your contracts actually cover the codes you intend to bill. Credentialing and enrollment commonly run 90–180 days per payer, and nothing about a new service line accelerates it. Map the payers that matter in your market, verify their esketamine policies (medical vs. pharmacy benefit, site-of-care rules, PA criteria), and start enrollment before you sign a drug distributor agreement. A REMS-certified clinic with no in-network payers is a very expensive waiting room. Our credentialing services page covers how we run this.
3. The Drug Acquisition Decision: Buy-and-Bill vs. Specialty Pharmacy
Buy-and-Bill
You purchase drug from an authorized specialty distributor, hold inventory, and bill the payer’s medical benefit alongside the administration. Upside: on-demand inventory and scheduling flexibility — a same-week induction is possible. Downside: you carry drug cost on your balance sheet, and an unpaid claim means you ate the drug, which is why benefit verification and auth tracking must be airtight first.
Specialty Pharmacy (White-Bagging)
A REMS-certified specialty pharmacy bills the patient’s pharmacy benefit and ships patient-labeled drug to your clinic per session. Upside: no inventory capital or carrying risk. Downside: every appointment acquires a shipment dependency — reschedules, benefit changes, and shipping misses all land on your calendar, and patient-labeled product generally cannot be reused for anyone else.
Reality: Most Programs Run Both
Payer benefit design usually decides the pathway per patient, not your preference. Plan for a hybrid from the start: two intake workflows, two billing patterns, and a scheduling system that knows which pathway each patient is on.
4. Space, Staffing, and the Monitoring Model
Every session requires at least two hours of post-dose monitoring by a healthcare provider on-site, so capacity is a physical design question: how many monitored chairs or rooms, covered by how many staff, for how many hours a day. Practical planning points:
- Rooms/chairs: Calm, low-stimulation spaces with recliners; patients experiencing dissociation do not belong in a bright open bay next to intake.
- Monitoring coverage: A nurse or equivalent healthcare provider covering a defined number of concurrent chairs, with vitals cadence (blood pressure, pulse oximetry) built into a flowsheet; prescriber available per protocol and state rules.
- Throughput math: sessions/day ≈ chairs × staffed hours ÷ ~2.5. Fifteen sessions a day on a 7am–7pm window takes roughly four concurrent monitored chairs — that is a staffing budget line, decided before launch, not after the waitlist forms.
- Ride-home logistics: Patients cannot drive until the next day; make ride confirmation a required scheduling field.
5. The Scheduling Template: Induction Is a Different Animal Than Maintenance
The labeled schedule — twice weekly in weeks 1–4, weekly in weeks 5–8, then every one to two weeks — means every new patient consumes eight induction slots in their first month, then progressively fewer. Two consequences for your template:
- Reserve induction capacity. If maintenance patients fill every slot, you cannot start new patients and the program stops growing. Hold dedicated induction blocks (e.g., fixed morning pairs on Monday/Thursday and Tuesday/Friday) so twice-weekly cadences can actually be booked as pairs.
- Book the cadence, not the visit. Schedule the full induction arc at intake and track adherence to it — payers read big schedule gaps as a medical-necessity question at reauthorization. A live cadence view is one of the highest-value pieces of tooling a program can have; the interventional psychiatry scheduler on our custom software and automation page (demo video there) was built for exactly this.
6. Financial Model Basics
Model the program before launch with honest inputs: drug acquisition cost per session under buy-and-bill versus zero drug capital under white-bagging; expected reimbursement per session by payer (Medicare’s bundled G2082/G2083 versus commercial drug-plus-services patterns — see the billing guide); staff cost per monitored hour; realistic ramp (a program’s first quarter is induction-heavy and capacity-light); and a no-show/cancellation assumption, because each missed slot is a 2.5-hour block and, on the pharmacy pathway, possibly a stranded shipment. The model does not need to be fancy. It needs to tell you your break-even sessions per day and how many days of auth-lapse leakage would erase your margin — because that number is usually smaller than owners expect.
Common Launch Mistakes
Certifying Before Contracting
REMS certification takes weeks; payer enrollment takes months. Teams that do them in that order launch with a certified site and no way to get paid.
No Authorization Tracking From Day One
At five patients you can remember the auth dates. At forty you cannot, and the failure arrives silently. Build the tracker before you need it — see authorization tracking.
Underpricing the Two-Hour Chair
Programs that model Spravato like a med-management visit discover their staffing cost per session too late. The monitoring window is the cost center; model it explicitly.
Treating Benefit Verification as Optional
Pathway (medical vs. pharmacy benefit), patient responsibility, and PA requirements verified per patient, in writing, before induction — or the first denial becomes the program’s tuition payment.
Launching a Spravato Program? Sequence It Right the First Time.
We help clinics stand up the operational and revenue infrastructure — credentialing, verification workflows, auth tracking, scheduling — before the first induction, not after the first denial.
Common Questions
How long does it take to launch a Spravato program?
Plan on roughly three to six months end to end. REMS setting certification and staff training are measured in weeks; payer credentialing and enrollment are the long pole at commonly 90–180 days per payer, which is why contracting starts first.
What equipment does a Spravato clinic need?
Modest but specific: comfortable low-stimulation treatment spaces, blood pressure monitoring, a pulse oximeter (required under current REMS provisions), emergency protocols, and secure drug storage if you run buy-and-bill. The larger investment is staffing the monitoring window, not equipment.
Should a new program choose buy-and-bill or specialty pharmacy?
Usually you do not get to choose globally — each payer’s benefit design tends to dictate the pathway per patient. Decide which pathway you prefer when both are possible, and build workflows for both from day one.
How many patients does a Spravato program need to be viable?
It depends on payer mix, reimbursement, and staffing cost, which is why the pre-launch financial model matters. The structural point: induction patients consume eight slots in month one, so capacity and break-even should be modeled in sessions per day, not patient counts.
Can a PMHNP-owned practice launch a Spravato program?
In many states, yes, subject to scope-of-practice and payer enrollment rules — the REMS certifies the setting, and prescribing authority follows state law. See our PMHNP hub for state-by-state practice requirements.